Vitexin, an inhibitor of hypoxia-inducible factor-1α, enhances the radiotherapy sensitization of hyperbaric oxygen on glioma

  • T. Xie
  • J.-R. Wang
  • C.-G. Dai
  • X.-A. FuEmail author
  • J. DongEmail author
  • Q. Huang
Research Article



Vitexin, an inhibitor of hypoxia-inducible factor (HIF)-1α, has anti-tumor effect. However, whether it can enhance the radiotherapy sensitization of hyperbaric oxygen (HBO) on glioma is unclear. This study aimed to investigate the effect of vitexin.


The nude mice with paw-transplanted glioma were divided into four groups: control group, HBO + radiation group, HBO + vitexin group, and HBO + vitexin + radiation group. The mice of last two groups were daily given vitexin 75 mg/kg by intraperitoneal injection. 30 min after administration of vitexin, the HBO-treated mice were daily placed in HBO chamber for 60 min. The radiation-treated mice were given local tumor irradiation once every week during the HBO treatment, and the dose of irradiation was 10 Gy/time. The experimental treatment lasted for 21 days.


Compared with the HBO + radiation group, the tumor volume, tumor weight, and tumor weight coefficient in the HBO + vitexin + radiation group were lower (p < 0.05). Importantly, the contents of reduced glutathione and glutathione peroxidase as well as expressions of HIF-1α, vascular endothelial growth factor, glucose transporter (GLUT)-1, and GLUT-3 proteins in tumor tissues were also lower in the HBO + vitexin + radiation group than in the HBO + radiation group (p < 0.01).


Vitexin can cooperate with HBO to sensitize the glioma radiotherapy, and its mechanisms may be correlated to the inhibition of HIF-1α protein expression and subsequent decrements of its downstream protein expressions, which finally cause the reduction of antioxidant capacity.


Glioma Vitexin Hyperbaric oxygen Radiotherapy sensitization HIF-1α 



This work was supported by the Science & Technology Project for Medical Health of Suzhou New District (no. 2017Q011).

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

All the procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.

Informed consent

Informed consent is not required for this type of study.


  1. 1.
    Razek AAKA, Talaat M, El-Serougy L, Gaballa G, Abdelsalam M. Clinical applications of arterial spin labeling in brain tumors. J Comput Assist Tomogr. 2019;43(4):525–32.PubMedGoogle Scholar
  2. 2.
    Razek AAKA, Talaat M, El-Serougy L, Abdelsalam M, Gaballa G. Differentiating glioblastomas from solitary brain metastases using arterial spin labeling perfusion- and diffusion tensor imaging-derived metrics. World Neurosurg. 2019;127:E593–8.CrossRefGoogle Scholar
  3. 3.
    El-Serougy L, Razek AAKA, Ezzat A, Eldawoody H, El-Morsy A. Assessment of diffusion tensor imaging metrics in differentiating low-grade from high-grade gliomas. Neuroradiol J. 2016;29(5):400–7.CrossRefGoogle Scholar
  4. 4.
    Chen JR, Xu HZ, Ding JB, Qin ZY. Radiotherapy after hyperbaric oxygenation in malignant gliomas. Curr Med Res Opin. 2015;31(11):1977–84.CrossRefGoogle Scholar
  5. 5.
    Braks JAM, Spiegelberg L, Koljenovic S, Ridwan Y, Keereweer S, Kanaar R, et al. Optical imaging of tumor response to hyperbaric oxygen treatment and irradiation in an orthotopic mouse model of head and neck squamous cell carcinoma. Mol Imaging Biol. 2015;17(5):633–42.CrossRefGoogle Scholar
  6. 6.
    Lu ZH, Ma JW, Liu B, Dai CG, Xie T, Ma XY, et al. Hyperbaric oxygen therapy sensitizes nimustine treatment for glioma in mice. Cancer Med. 2016;5(11):3147–55.CrossRefGoogle Scholar
  7. 7.
    Kohshi K, Beppu T, Tanaka K, Ogawa K, Inoue O, Kukita K, et al. Potential roles of hyperbaric oxygenation in the treatments of brain tumors. Undersea Hyperb Med. 2013;40(4):351–62.PubMedGoogle Scholar
  8. 8.
    Harada H, Inoue M, Itasaka S, Hirota K, Morinibu A, Shinomiya K, et al. Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate toward tumour blood vessels. Nat Commun. 2012;3:783.CrossRefGoogle Scholar
  9. 9.
    Zhang T, Niu XH, Liao LL, Cho EA, Yang HF. The contributions of HIF-target genes to tumor growth in RCC. PLoS ONE. 2013;8(11):e80544.CrossRefGoogle Scholar
  10. 10.
    Tang L, Wei F, Wu YF, He Y, Shi L, Xiong F, et al. Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res. 2018;37:87.Google Scholar
  11. 11.
    Harada H. Hypoxia-inducible factor 1-mediated characteristic features of cancer cells for tumor radioresistance. J Radiat Res. 2016;57(Suppl 1):i99–105.CrossRefGoogle Scholar
  12. 12.
    He M, Min JW, Kong WL, He XH, Li JX, Peng BW. A review on the pharmacological effects of vitexin and isovitexin. Fitoterapia. 2016;115:74–85.CrossRefGoogle Scholar
  13. 13.
    Liu XL, Jiang QF, Liu HM, Luo SX. Vitexin induces apoptosis through mitochondrial pathway and PI3K/Akt/mTOR signaling in human non-small cell lung cancer A549 cells. Biol Res. 2019;52:7.CrossRefGoogle Scholar
  14. 14.
    Zhang GN, Li DY, Chen H, Zhang JC, Jin XY. Vitexin induces G2/M-phase arrest and apoptosis via Akt/mTOR signaling pathway in human glioblastoma cells. Mol Med Rep. 2018;17(3):4599–604.PubMedGoogle Scholar
  15. 15.
    Bhardwaj M, Cho HJ, Paul S, Jakhar R, Khan I, Lee SJ, et al. Vitexin induces apoptosis by suppressing autophagy in multi-drug resistant colorectal cancer cells. Oncotarget. 2018;9(3):3278–91.CrossRefGoogle Scholar
  16. 16.
    Yang HP, Huang J, Mao YF, Wang L, Lie RD, Ha CZ. Vitexin alleviates interleukin-1beta-induced inflammatory responses in chondrocytes from osteoarthritis patients: involvement of HIF-1alpha pathway. Scand J Immunol. 2019;90(2):UNSPe12773.Google Scholar
  17. 17.
    Min JW, Hu JJ, He M, Sanchez RM, Huang WX, Liu YQ, et al. Vitexin reduces hypoxia-ischemia neonatal brain injury by the inhibition of HIF-1 alpha in a rat pup model. Neuropharmacology. 2015;99:38–50.CrossRefGoogle Scholar
  18. 18.
    Zhu YD, Dai XL, Zhao DL, Sun C, Dong J, Huang Q. The effect of glioma stem/progenitor cell on tumor angiogenesis traced by red/green fluorescent protein. Chin J Exp Surg. 2013;30:297–9.Google Scholar
  19. 19.
    Zhu ZY, Gao T, Huang Y, Xue J, Xie ML. Apigenin ameliorates hypertension-induced cardiac hypertrophy and down-regulates cardiac hypoxia inducible factor-lα in rats. Food Funct. 2016;7:1992–8.CrossRefGoogle Scholar
  20. 20.
    Zhang Y, Martin SG. Redox proteins and radiotherapy. Clin Oncol. 2014;26(5):289–300.CrossRefGoogle Scholar
  21. 21.
    Nakayama M, Sasaki R, Ogino C, Tanaka T, Morita K, Umetsu M, et al. Titanium peroxide nanoparticles enhanced cytotoxic effects of X-ray irradiation against pancreatic cancer model through reactive oxygen species generation in vitro and in vivo. Radiat Oncol. 2016;11:91.CrossRefGoogle Scholar
  22. 22.
    Wu JQ, Kosten TR, Zhang XY. Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:200–6.CrossRefGoogle Scholar
  23. 23.
    An F, Cao XX, Qu HQ, Wang SH. Attenuation of oxidative stress of erythrocytes by the plant-derived flavonoids vitexin and apigenin. Pharmazie. 2015;70(11):724–32.PubMedGoogle Scholar
  24. 24.
    Lu Y, Yu T, Liu JY, Gu LN. Vitexin attenuates lipopolysaccharide-induced acute lung injury by controlling the Nrf2 pathway. PLoS ONE. 2018;13(4):e0196405.CrossRefGoogle Scholar
  25. 25.
    Sun Z, Yan B, Yu WY, Yao XP, Ma XJ, Sheng GL, Ma Q. Vitexin attenuates acute doxorubicin cardiotoxicity in rats via the suppression of oxidative stress, inflammation and apoptosis and the activation of FOXO3a. Exp Ther Med. 2016;12(3):1879–84.CrossRefGoogle Scholar
  26. 26.
    Nakashima R, Goto Y, Koyasu S, Kobayashi M, Morinibu A, Yoshimura M, et al. UCHL1-HIF-1 axis-mediated antioxidant property of cancer cells as a therapeutic target for radiosensitization. Sci Rep. 2017;7:6879.CrossRefGoogle Scholar
  27. 27.
    Luo ZH, Bai MH, Xiao X, Zhang W, Liu XD, Yang XL, et al. Silencing of HIF-1 alpha enhances the radiation sensitivity of human glioma growth in vitro and in vivo. Neuropharmacology. 2015;89:168–74.CrossRefGoogle Scholar
  28. 28.
    Jin L, Zhou YH. Crucial role of the pentose phosphate pathway in malignant tumors. Oncol Lett. 2019;17(5):4213–21.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Cho ES, Cha YH, Kim HS, Kim NH, Yook JI. The pentose phosphate pathway as a potential target for cancer therapy. Biomol Ther. 2018;26(1):29–38.CrossRefGoogle Scholar
  30. 30.
    Gong C, Yang ZY, Zhang LY, Wang YH, Gong W, Liu Y. Quercetin suppresses DNA double-strand break repair and enhances the radiosensitivity of human ovarian cancer cells via p53-dependent endoplasmic reticulum stress pathway. Onco Targets Ther. 2018;11:17–27.CrossRefGoogle Scholar
  31. 31.
    Zhang Y, Wei YM, Zhu ZY, Gong WP, Liu X, Hou QS, et al. Icariin enhances radiosensitivity of colorectal cancer cells by suppressing NF-kappa B activity. Cell Biochem Biophys. 2014;69(2):303–10.CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2019

Authors and Affiliations

  1. 1.Department of Neurosurgery, Suzhou Municipal HospitalThe Affiliated Suzhou Hospital of Nanjing Medical UniversitySuzhouChina
  2. 2.The Experimental Center and Department of NeurosurgeryThe Second Affiliated Hospital of Soochow UniversitySuzhouChina

Personalised recommendations